News

Enhancing Sales Excellence in the Pharmaceutical Industry through Targeted Training

Good Sales Practices for Pharmaceuticals

The training aims to enhance the competence of the company’s employees in order to meet the continuously growing demands and to seize opportunities in sales. In doing so, the foundation for the company’s economic success is further strengthened.

Publishing Date:
Friday, 6 June, 2025

Download article as PDF

Categories

About Evidentic

Evidentic is a young innovative company providing original drugs for research and new drug development.
Through our unique concept, we enable our customers to buy small quantities of these drugs as consumables, saving costs and time.

Follow Us

Read more

News

Digitalization and Automation: Building Smarter Processes for Sustainable Growth

News

Incubators: Cultivating Innovation in Life Sciences

Incubators, by offering resources and guidance, fuel innovation in life sciences by accelerating progress, boosting success rates, and fostering a vibrant ecosystem.

Scientific Resources

Solubility of ADCs: influencing factors and optimization tips

The solubility of ADCs is a critical factor not only for clinical efficacy and safety, but also for manufacturability. Here, we will discuss the factors that affect the solubility of ADCs and how to optimize their solubility.

Scientific Resources

How to identify the right molecule for your assay

Why you should distinguish clinical-grade from research-grade molecules

News

Biologic drugs approvals in 2021

Approvals of biologic drugs from EMA and FDA include new molecular entities (NMEs), expanded therapeutic indications, new dosage forms, novel formulations, and biosimilars. In the light of COVID-19, much of the biologic EUAs pertain to vaccines and anti-viral drugs against the SARS-CoV-2 virus. In addition, a number of breakthrough innovations have been approved for rare diseases, which is consistent with the current shift towards speciality drugs in the pharma industry.

News, Scientific Resources

Therapeutic antibodies against Omicron and new variants

The new variant of SARS CoV-2, B.1.1.529 Omicron, was designated as a variant of concern (VOC) by the World Health Organization (WHO). The virus's capacity to bind to ACE2 continues to be a key factor in its pathogenicity. Drugs for prophylactic therapy or preventing adverse effects are still under development. Even though Omicron is more transmissible than delta and resistant to most vaccinations and monoclonal antibodies, we still have at least two authorized monoclonal antibody treatments- Sotrovimab and Evusheld.